menu search

Amazon stock: bear vs. bull

Amazon's stock is up over 50% year to date. The company appears to be on a growth path, leading two exp...

October 14, 2023, 9:20 am

Tscan therapeutics: that recent amgen deal is the only point of interest

TScan Therapeutics is developing TCR T-cell therapies for cancer using a transposon-based T cell engineering method. The company aims to target a broa...

October 14, 2023, 3:32 am

The weekly bottom line: goodbye “how high”, hello “how long”

U.S. Highlights U.S. bond yields retreated from highs reached last week, as heightened geopolitical risks in the Middle East boosted investors demand ...

October 14, 2023, 2:15 am

Bragar eagel & squire, p.c. reminds investors that class action lawsuits have been filed against dfs, uipath, and tandem and encourages investors to contact the firm

NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that ...

October 14, 2023, 1:00 am

Sec will not appeal grayscale’s court win over spot bitcoin etf conversion

The decision, which comes after a legal battle and months of anticipation, may signal a shift in the re...

October 13, 2023, 10:14 pm

Eur/usd forecast: faces pressure following cpi surprise

In Thursday’s trading session, the euro experienced a significant decline in response to higher-than-anticip...

October 13, 2023, 6:44 pm

Mind medicine: q4 of 2023 data for gad makes this worth a look

Results from the phase 2b study, using MM-120 for the treatment of patients with generalized anxiety di...

October 13, 2023, 6:37 pm

Amazon health services 'connecting the dots' to create more access points

"Online retailer Amazon's (AMZN) pivot into the healthcare space has had a rapid rise. Amazon Health Services SVP Neil Lindsay sat down with Yahoo Fin...

October 13, 2023, 6:12 pm

Alnylam pharmaceuticals: a good buy ahead of phase 3 data for vutrisiran

We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for ...

October 13, 2023, 6:11 pm

Pfizer slashes full-year earnings and revenue guidance as covid treatment, vaccine sales slump

Pfizer said it anticipates sales of its Covid treatment Paxlovid and its vaccine will be $9 billion les...

October 13, 2023, 5:47 pm

Processa pharmaceuticals to present at the thinkequity conference

HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage ...

October 13, 2023, 5:08 pm

Kronos bio presents positive preliminary data from phase 1 dose escalation portion of phase 1/2 kb-0742 study at aacr-nci-eortc

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transc...

October 13, 2023, 4:30 pm

Harmony stock tanks on study miss for narcolepsy drug: problems may be escalating

Harmony Biosciences' only product, WAKIX - pitolisant - has generated over $1 billion in net revenue since its launch. The company's Q2 2023 earnings ...

October 13, 2023, 4:01 pm

Amc's stock slides more than 13% despite taylor swift concert film opening

Shares of AMC Entertainment Holdings Inc. are down 13.8% despite the eagerly anticipated opening of the...

October 13, 2023, 3:59 pm

Weekly summary and review 13th october 2023

Hi Traders! Arvinth here from the Home Trader Club team. The weekly summary and, review of October 13th 2023 is here. It is now time to recap and summ...

October 13, 2023, 3:35 pm

Ehang: certification received, commercial liftoff

EHang Holdings has received certification for its EH216-S after suspending the trading of its American depositary shares earlier this week. EH stock h...

October 13, 2023, 3:10 pm

Chesapeake energy and the electrification of energy demand

Anticipated surge in U.S.-based natural gas demand in 2024 highlights Chesapeake Energy Corporation's p...

October 13, 2023, 3:10 pm

Syndax: biotech to watch with regulatory filings before end of 2023

Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relapsed/refractory leukemia ...

October 13, 2023, 2:52 pm

U.s. consumer sentiment slumps much more than expected in october

Consumer sentiment in the U.S. has deteriorated by much more than anticipated in the month of October, ...

October 13, 2023, 2:34 pm

Cidara therapeutics and mundipharma receive positive chmp opinion for rezafungin for the treatment of invasive candidiasis in adults(1)

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and e...

October 13, 2023, 2:34 pm


Search within

Pages Search Results: